{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:41:14Z","timestamp":1790152874794,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s42000-024-00535-0","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T08:03:22Z","timestamp":1709193802000},"page":"759-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient"],"prefix":"10.1007","volume":"23","author":[{"given":"Calogera Claudia","family":"Spagnolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Campenn\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cardile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacarmela","family":"Santarpia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria Maddalena","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"535_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"535_CR2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N et al (2022) Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 23:781\u2013792. https:\/\/doi.org\/10.1016\/S1470-2045(22)00226-1","journal-title":"Lancet Oncol"},{"key":"535_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","volume":"33","author":"J Niu","year":"2022","unstructured":"Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M et al (2022) First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann Oncol 33:169\u2013180. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.002","journal-title":"Ann Oncol"},{"key":"535_CR4","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I et al (2022) COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol 40:3383\u20133393. https:\/\/doi.org\/10.1200\/JCO.22.00227","journal-title":"J Clin Oncol"},{"key":"535_CR5","doi-asserted-by":"publisher","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","volume":"13","author":"H Mamdani","year":"2022","unstructured":"Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI (2022) Immunotherapy in lung cancer: current landscape and future directions. Front Immunol 13:823618. https:\/\/doi.org\/10.3389\/fimmu.2022.823618","journal-title":"Front Immunol"},{"key":"535_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B (2021) Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 23:39. https:\/\/doi.org\/10.1208\/s12248-021-00574-0","journal-title":"AAPS J"},{"key":"535_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E et al (2022) Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386:24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"key":"535_CR8","doi-asserted-by":"publisher","unstructured":"Spagnolo CC, Giuffrida G, Cannavo S, Franchina T, Silvestris N, Ruggeri RM et al (2022) Management of endocrine and metabolic toxicities of immune-checkpoint inhibitors: from clinical studies to a real-life scenario. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15010246","DOI":"10.3390\/cancers15010246"},{"key":"535_CR9","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s40618-023-02096-2","volume":"46","author":"RM Ruggeri","year":"2023","unstructured":"Ruggeri RM, Spagnolo CC, Alibrandi A, Silvestris N, Cannavo S, Santarpia M (2023) Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center. J Endocrinol Invest 46:2399\u20132409. https:\/\/doi.org\/10.1007\/s40618-023-02096-2","journal-title":"J Endocrinol Invest"},{"key":"535_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40:17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"535_CR11","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS et al (2021) Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 106:e3704\u2013e3713. https:\/\/doi.org\/10.1210\/clinem\/dgab263","journal-title":"J Clin Endocrinol Metab"},{"key":"535_CR12","doi-asserted-by":"publisher","first-page":"886930","DOI":"10.3389\/fendo.2022.886930","volume":"13","author":"CA Muir","year":"2022","unstructured":"Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ (2022) Immune related adverse events of the thyroid - a narrative review. Front Endocrinol 13:886930. https:\/\/doi.org\/10.3389\/fendo.2022.886930","journal-title":"Front Endocrinol"},{"key":"535_CR13","doi-asserted-by":"publisher","first-page":"S689","DOI":"10.1053\/j.seminoncol.2023.11.003","volume":"34","author":"MW Lucas","year":"2023","unstructured":"Lucas MW, Helderman NC, van de Velde AO et al (2023) Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pancancer cohort of 4314 patients. Ann Oncol 34:S689. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.11.003","journal-title":"Ann Oncol"},{"key":"535_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.eprac.2020.09.016","volume":"27","author":"Y Shi","year":"2021","unstructured":"Shi Y, Shen M, Zheng X, Yang T (2021) Immune checkpoint inhibitor-induced adrenalitis and primary adrenal insufficiency: systematic review and optimal management. Endocr Pract 27:165\u2013169. https:\/\/doi.org\/10.1016\/j.eprac.2020.09.016","journal-title":"Endocr Pract"},{"key":"535_CR15","doi-asserted-by":"publisher","unstructured":"Shi Y, Shen M, Zheng X, Chen Y, Zhao R, Gu Y et al (2020) ICPis-induced autoimmune polyendocrine syndrome type 2: a review of the literature and a protocol for optimal management. J Clin Endocrinol Metab 105. https:\/\/doi.org\/10.1210\/clinem\/dgaa553","DOI":"10.1210\/clinem\/dgaa553"},{"key":"535_CR16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00262-020-02699-1","volume":"70","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Wang X, Bao XQ, Ning J, Shang M, Zhang D (2021) Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review. Cancer Immunol Immunother 70:1527\u20131540. https:\/\/doi.org\/10.1007\/s00262-020-02699-1","journal-title":"Cancer Immunol Immunother"},{"key":"535_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross M et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472\u2013492. https:\/\/doi.org\/10.3322\/caac.21409","journal-title":"CA Cancer J Clin"},{"key":"535_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"535_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"Ruggeri RM, Campenni A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F et al (2019) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 42:745\u2013756. https:\/\/doi.org\/10.1007\/s40618-018-0984-z","journal-title":"J Endocrinol Invest"},{"key":"535_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12020-021-02750-w","volume":"74","author":"R Rubino","year":"2021","unstructured":"Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I et al (2021) Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. Endocrine 74:172\u2013179. https:\/\/doi.org\/10.1007\/s12020-021-02750-w","journal-title":"Endocrine"},{"key":"535_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40618-019-01112-8","volume":"43","author":"EM Presotto","year":"2020","unstructured":"Presotto EM, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N et al (2020) Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. J Endocrinol Invest 43:337\u2013345. https:\/\/doi.org\/10.1007\/s40618-019-01112-8","journal-title":"J Endocrinol Invest"},{"key":"535_CR22","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB et al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9. https:\/\/doi.org\/10.1136\/jitc-2021-002435","DOI":"10.1136\/jitc-2021-002435"},{"key":"535_CR23","doi-asserted-by":"publisher","first-page":"1157805","DOI":"10.3389\/fendo.2023.1157805","volume":"14","author":"Z Cardona","year":"2023","unstructured":"Cardona Z, Sosman JA, Chandra S, Huang W (2023) Endocrine side effects of immune checkpoint inhibitors. Front Endocrinol 14:1157805. https:\/\/doi.org\/10.3389\/fendo.2023.1157805","journal-title":"Front Endocrinol"},{"key":"535_CR24","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","volume":"7","author":"C Ma","year":"2019","unstructured":"Ma C, Hodi FS, Giobbie-Hurder A, Wang X, Zhou J, Zhang A et al (2019) The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders. Cancer Immunol Res 7:1214\u20131220. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0613","journal-title":"Cancer Immunol Res"},{"key":"535_CR25","doi-asserted-by":"publisher","unstructured":"Li J, Yang K, Zhao L, Bai C, Sun Z  Impact of corticosteroids use on efficacy of immune checkpoint inhibitors in cancer patients: a meta-analysis. J Clin Oncol 38(15_suppl). https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e15234","DOI":"10.1200\/JCO.2020.38.15_suppl.e15234"},{"key":"535_CR26","doi-asserted-by":"publisher","unstructured":"Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L et al (2020) Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers 12. https:\/\/doi.org\/10.3390\/cancers12030546","DOI":"10.3390\/cancers12030546"},{"key":"535_CR27","doi-asserted-by":"publisher","first-page":"928390","DOI":"10.3389\/fonc.2022.928390","volume":"12","author":"S Bruera","year":"2022","unstructured":"Bruera S, Suarez-Almazor ME (2022) The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol 12:928390. https:\/\/doi.org\/10.3389\/fonc.2022.928390","journal-title":"Front Oncol"},{"key":"535_CR28","doi-asserted-by":"publisher","first-page":"100374","DOI":"10.1016\/j.iotech.2023.100374","volume":"17","author":"NC Helderman","year":"2023","unstructured":"Helderman NC, Lucas MW, Blank CU (2023) Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors. Immunooncol Technol 17:100374. https:\/\/doi.org\/10.1016\/j.iotech.2023.100374","journal-title":"Immunooncol Technol"},{"key":"535_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ando.2018.07.002","volume":"79","author":"M Haissaguerre","year":"2018","unstructured":"Haissaguerre M, Hescot S, Bertherat J, Chabre O (2018) Expert opinions on adrenal complications in immunotherapy. Ann Endocrinol 79:539\u2013544. https:\/\/doi.org\/10.1016\/j.ando.2018.07.002","journal-title":"Ann Endocrinol"},{"key":"535_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1210\/js.2018-00366","volume":"3","author":"G Lanzolla","year":"2019","unstructured":"Lanzolla G, Coppelli A, Cosottini M, Del Prato S, Marcocci C, Lupi I (2019) Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome. J Endocr Soc 3:496\u2013503. https:\/\/doi.org\/10.1210\/js.2018-00366","journal-title":"J Endocr Soc"},{"key":"535_CR31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1210\/js.2017-00170","volume":"1","author":"AC Paepegaey","year":"2017","unstructured":"Paepegaey AC, Lheure C, Ratour C, Lethielleux G, Clerc J, Bertherat J et al (2017) Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma. J Endocr Soc 1:646\u2013649. https:\/\/doi.org\/10.1210\/js.2017-00170","journal-title":"J Endocr Soc"},{"key":"535_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"535_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.13063","volume":"85","author":"MN Joshi","year":"2016","unstructured":"Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV (2016) Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol 85:331\u2013339. https:\/\/doi.org\/10.1111\/cen.13063","journal-title":"Clin Endocrinol"},{"key":"535_CR34","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","volume":"9","author":"M Stelmachowska-Banas","year":"2020","unstructured":"Stelmachowska-Banas M, Czajka-Oraniec I (2020) Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect 9:R207\u2013R228. https:\/\/doi.org\/10.1530\/EC-20-0342","journal-title":"Endocr Connect"},{"key":"535_CR35","doi-asserted-by":"publisher","unstructured":"Martella S, Lucas M, Porcu M, Perra L, Denaro N, Pretta A et al (2023) Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects. Semin Oncol. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.11.003","DOI":"10.1053\/j.seminoncol.2023.11.003"},{"key":"535_CR36","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","volume":"40","author":"S Bacanovic","year":"2015","unstructured":"Bacanovic S, Burger IA, Stolzmann P, Hafner J, Huellner MW (2015) Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT. Clin Nucl Med 40:e518\u2013e519. https:\/\/doi.org\/10.1097\/RLU.0000000000000887","journal-title":"Clin Nucl Med"},{"key":"535_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2214\/AJR.15.15480","volume":"207","author":"SA Howard","year":"2016","unstructured":"Howard SA, Krajewski KM, Jagannathan JP, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB et al (2016) A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumor response, and effect on metastasectomy. AJR Am J Roentgenol 207:4\u201314. https:\/\/doi.org\/10.2214\/AJR.15.15480","journal-title":"AJR Am J Roentgenol"},{"key":"535_CR38","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMc1805308","volume":"378","author":"ES Husebye","year":"2018","unstructured":"Husebye ES, Anderson MS, Kampe O (2018) Autoimmune polyendocrine syndromes. N Engl J Med 378:2543\u20132544. https:\/\/doi.org\/10.1056\/NEJMc1805308","journal-title":"N Engl J Med"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-024-00535-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-024-00535-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-024-00535-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:10:44Z","timestamp":1730110244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-024-00535-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1007\/s42000-024-00535-0","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}